(3-甲基-1,2,4-噁二唑-5-基)甲胺 | 90928-92-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (3-甲基-1,2,4-噁二唑-5-基)甲胺
• 英文名称: (3-methyl-1,2,4-oxadiazol-5-yl)methanamine
• 英文别名: 3-Methyl-1,2,4-oxadiazol-5-ylmethylamine；F2185-0004；1-(3-methyl[1,2,4]oxadiazol-5-yl)methanamine；3-methyl-1,2,4-oxadiazole-5-methanamine；5-aminomethyl-3-methyl-1,2,4-oxadiazole
• CAS: 90928-92-0
• 化学式: C₄H₇N₃O
• mdl: MFCD10696386
• 分子量: 113.119
• InChiKey: NPBUMVMXXGQOEG-UHFFFAOYSA-N

物化性质

• 沸点：
  223.0±42.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  (3-甲基-1,2,4-噁二唑-5-基)甲胺 在 氢溴酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 1.0h， 生成 5-(bromomethyl)-3-methyl-1,2,4-oxadiazole
  参考文献：
  名称：

  SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

  摘要：

  揭示了具有以下通用公式（I）的化合物，其制备方法以及用于预防或治疗涉及与促进素2受体相关的任何疾病的用途，如肥胖、食欲或味觉障碍，包括虚弱、厌食症和暴食症、糖尿病、代谢综合征、呕吐和恶心、抑郁和焦虑、成瘾、情绪和行为障碍、精神分裂症、睡眠障碍、不宁腿综合征、记忆学习障碍、性和心理性功能障碍、疼痛、内脏或神经痛、疼痛过敏、消化障碍、肠易激综合征、神经元退行性疾病、缺血性或出血性发作、库欣氏病、吉兰-巴雷综合征、肌强直性萎缩、尿失禁、甲状腺功能亢进、垂体功能障碍、高血压或低血压。

  公开号：

  US20070185136A1
• 作为产物：
  描述：

  2-甲基-2-丙基[(3-甲基-1,2,4-恶二唑-5-基)甲基]氨基甲酸酯 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 (3-甲基-1,2,4-噁二唑-5-基)甲胺
  参考文献：
  名称：

  Synthesis and pharmacological profile of a series of 2,5-substituted-N,N-dimethyltryptamine derivatives as novel antagonists for the vascular 5-HT1B-like receptor

  摘要：

  冠状动脉5-HT1B样受体与血管痉挛有关，并且推测5-HT1B样拮抗剂可以阻断5-HT的有害作用，同时不干扰正常的血管功能。一系列新型 2-(N-杂芳基)甲酰氨基-5-取代-N,N-二甲基色胺衍生物的合成和药理学概况为沉默（通过血管紧张素 II 无法揭露 5-HT1B 样受体介导的激动剂来判断）描述了竞争性和选择性 5-HT1B 样受体拮抗剂。探索了对 2-甲酰胺基侧链以及 5-亚乙基连接的杂环的修饰。发现 N-糠基-5-[2-(N-邻苯二甲酰亚胺)乙基]-3-[2-(二甲氨基)乙基]-1H-吲哚-2-甲酰胺 (34)，它满足我们的体外选择标准，并且具有良好的药代动力学特征。化合物 34 对血管 5-HT1B 样受体表现出良好的亲和力 (pKB = 7.38)，选择性比 α1-肾上腺素受体亲和力高 125 倍以上。讨论了 34 种及相关化合物相对于其他受体亚型对 5-HT1B 样受体的选择性，并提出了此类化合物与药效团模型的结合模式。

  DOI：

  10.1039/a903328i

文献信息

• [EN] OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS OXADIAZOLE QUI INHIBENT L'ACTIVITÉ DE LA BÊTA-SECRÉTASE, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：COMENTIS INC

  公开号：WO2012054510A1

  公开（公告）日：2012-04-26

  The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.

  这项发明提供了新型β-分泌酶抑制剂以及它们的方法，包括治疗阿尔茨海默病的方法。
• Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors
  作者：Matthew F. Sammons、Sujay V. Kharade、Kevin J. Filipski、Markus Boehm、Aaron C. Smith、Andre Shavnya、Dilinie P. Fernando、Matthew S. Dowling、Philip A. Carpino、Neil A. Castle、Shannon G. Zellmer、Brett M. Antonio、James R. Gosset、Anthony Carlo、Jerod S. Denton

  DOI：10.1021/acsmedchemlett.7b00481

  日期：2018.2.8

  Inhibitors of the renal outer medullary potassium channel (ROMK) show promise as novel mechanism diuretics, with potentially lower risk of diuretic-induced hypokalemia relative to current thiazide and loop diuretics. Here, we report the identification of a novel series of 3-sulfamoylbenzamide ROMK inhibitors. Starting from HTS hit 4, this series was optimized to provide ROMK inhibitors with good in

  肾外髓质钾通道（ROMK）抑制剂有望作为新型机制利尿剂，与目前的噻嗪类和loop利尿剂相比，利尿剂引起的低钾血症的风险可能更低。在这里，我们报告的新型3-氨磺酰苯甲酰胺ROMK抑制剂的鉴定。从HTS 4开始，对该系列进行了优化，以为ROMK抑制剂提供良好的体外效能和均衡的ADME谱。与先前报道的小分子ROMK抑制剂相反，该系列成员被证明对人类的抑制作用高于对大鼠ROMK的抑制作用，并且对消除先前报道的ROMK抑制剂的抑制活性的N171D孔突变不敏感。
• 2-cyano-2-alkoximino-acetamides
  申请人：Bayer Aktiengesellschaft

  公开号：US04886833A1

  公开（公告）日：1989-12-12

  Novel fungicides of the formula ##STR1## in which R.sup.1 represents optionally substituted hydroxyalkyl, optionally substituted hydroxyalkoxyalkyl, optionally substituted heteroarylalkyl or optionally substituted heteroaryl, and R.sup.2 represents optionally substituted alkyl, optionally substituted alkenyl, or alkinyl. Intermediate therefor, wherein R.sup.2 is hydrogen or an alkali metal cation, are also new.

  新型杀菌剂的化学式为##STR1## 其中R.sup.1代表可选择置换的羟基烷基，可选择置换的羟基烷氧基烷基，可选择置换的杂环基烷基或可选择置换的杂环基，R.sup.2代表可选择置换的烷基，可选择置换的烯基或炔基。其中R.sup.2为氢或碱金属阳离子。其中间体，其中R.sup.2为氢或碱金属阳离子，也是新的。
• Non-peptide gnrh antagonists
  申请人：Roe Bryan Michael

  公开号：US20050222139A1

  公开（公告）日：2005-10-06

  Compounds according to general formula 1, wherein A 1 -A 3 are selected from A 5 and A 6 where A 5 is either ═CR 13 — or ═N— and A 6 is —NR 14 —, —O— or —S—; A 4 is either a covalent bond or A 5 , provided that when A 4 is a covalent bond one of A 1 -A 3 must be A 6 and the other two must be A 5 and when A 4 is A 5 then all of A 1 -A 3 must be A 5 ; R 1 is selected from H, NHY′ and COY 2 , in which case R 2 is H, or R 1 and R2 may both be methyl or together represent ═O; R 3 , R 4 and R 5 are each independently selected from H and lower alkyl groups; R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are each independently selected from H, lower alkyl groups, NH 2 , halogens (F, CI and Br) O-alkyl, CH 2 NM 2 and CF 3 ; R 13 is selected from H, F, CI Br, NO 2 , NH 2 , OH, Me, Et, OMe, NMe 2 and CF 3 ; R 14 is selected from H, methyl and ethyl; W is selected from ═CH— and ═N—; X is selected from CH 2 , O, S, SO 2 , NH and N lower alkyl; Y 1 is selected from CO-lower alkyl, CO(CH 2 ) b Y 3 , CO(CH 2 ) b COY 3 and CO(CH)NHCOY 3 , where b is 1-3; Y2 is selected from OR 15 , NR 16 R 17 and NH(CH 2 ) C COY 3 , where c is 1-3; Y 3 is selected from OR 15 and NR 16 R 17 ; R 15 is selected from H, lower alkyl and (CH 2 ) a R 16 , where a is 0-4; R 16 and R 17 are each independently selected from H, lower alkyl and (CH 2 ) a R 16 or together are —(CH 2 ) 2 -Z-(CH 2)2 —; R 18 is OH a phenyl group or an aromatic heterocycle selected from pyridyl, pyrimidinyl, pyrazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl and thiadiazolyl, each of which may optionally have a lower alkyl group substituent; and Z is selected from O, CH 2 , S, SO 2 , NH and N-lower alkyl, are new. They are useful in the treatment of breast and prostate cancer, endometriosis and benign prostate hyperplasia, in the regulation of fertility, and in in vitro fertilisation.

  化合物按照通式1进行选择，其中A1-A3选择自A5和A6，其中A5为═CR13—或═N—，A6为—NR14—，—O—或—S—；A4为共价键或A5，若A4为共价键，则A1-A3中必须有一个为A6，其余两个必须为A5，若A4为A5，则A1-A3全部必须为A5；R1选择自H、NHY′和COY2，此时R2为H，或者R1和R2都可以为甲基，或者一起代表═O；R3、R4和R5各自独立选择自H和较低的烷基基团；R6、R7、R8、R9、R10、R11和R12各自独立选择自H、较低的烷基基团、NH2、卤素（F、CI和Br）、O-烷基、CH2NM2和CF3；R13选择自H、F、CI、Br、NO2、NH2、OH、Me、Et、OMe、NMe2和CF3；R14选择自H、甲基和乙基；W选择自═CH—和═N—；X选择自CH2、O、S、SO2、NH和较低的烷基；Y1选择自CO-较低的烷基、CO(CH2)bY3、CO(CH2)bCOY3和CO(CH)NHCOY3，其中b为1-3；Y2选择自OR15、NR16R17和NH(CH2)CCOY3，其中c为1-3；Y3选择自OR15和NR16R17；R15选择自H、较低的烷基和(CH2)aR16，其中a为0-4；R16和R17各自独立选择自H、较低的烷基和(CH2)aR16，或者一起为—(CH2)2-Z-(CH2)2—；R18为OH、苯基或选择自吡啶基、嘧啶基、吡嗪基、呋喃基、噻吩基、吡咯基、咪唑基、吡唑基、噁唑基、异噁唑基、噻唑基、异噻唑基、三唑基、噁二唑基和噻二唑基的芳香杂环，每个都可以选择具有较低的烷基基团取代基；Z选择自O、CH2、S、SO2、NH和N-较低的烷基。它们在乳腺和前列腺癌、子宫内膜异位症和良性前列腺增生的治疗、生育调节以及体外受精方面有用。
• Non-peptide GnRH antagonists
  申请人：Roe Michael Bryan

  公开号：US20080255109A1

  公开（公告）日：2008-10-16

  Compounds according to general formula 1, wherein A 1 -A 3 are selected from A 5 and A 6 where A 5 is either ═CR 13 — or ═N— and A 6 is —NR 14 —, —O— or —S—; A 4 is either a covalent bond or A 5 , provided that when A 4 is a covalent bond one of A 1 -A 3 must be A 6 and the other two must be A 5 and when A 4 is A 5 then all of A 1 -A 3 must be A 5 ; R 1 is selected from H, NHY′ and COY 2 , in which case R 2 is H, or R 1 and R 2 may both be methyl or together represent ═O; R 3 , R 4 and R 5 are each independently selected from H and lower alkyl groups; R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are each independently selected from H, lower alkyl groups, NH 2 , halogens (F, Cl and Br) O-alkyl, CH 2 NM 2 and CF 3 ; R 13 is selected from H, F, Cl, Br, NO 2 , NH 2 , OH, Me, Et, OMe, NMe 2 and CF 3 ; R 14 is selected from H, methyl and ethyl; W is selected from ═CH— and ═N—; X is selected from CH 2 , O, S, SO 2 , NH and N-lower alkyl; Y 1 is selected from CO-lower alkyl, CO(CH 2 ) b Y 3 , CO(CH 2 ) b COY 3 and CO(CH 2 ) b NHCOY 3 , where b is 1-3; Y 2 is selected from OR 15 , NR 16 R 17 and NH(CH 2 ) c COY3, where c is 1-3; Y 3 is selected from OR 15 and NR 16 R 17 ; R 15 is selected from H, lower alkyl and (CH 2 ) a R 16 , where a is 0-4; R 16 and R 17 are each independently selected from H, lower alkyl and (CH 2 ) a R 16 or together are —(CH 2 ) 2 -Z-(CH 2 ) 2 —; R 18 is OH, a phenyl group or an aromatic heterocycle selected from pyridyl, pyrimidinyl, pyrazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl and thiadiazolyl, each of which may optionally have a lower alkyl group substituent; and Z is selected from O, CH 2 , S, SO 2 , NH and N-lower alkyl, are new. They are useful in the treatment of breast and prostate cancer, endometriosis and benign prostate hyperplasia, in the regulation of fertility, and in in vitro fertilisation.

  化合物的一般式为1，其中A1-A3从A5和A6中选择，其中A5是═CR13—或═N—，A6是—NR14—，—O—或—S—; A4是共价键或A5，如果A4是共价键，则A1-A3中必须有一个为A6，另外两个必须为A5，如果A4是A5，则A1-A3必须全部为A5; R1从H，NHY'和COY2中选择，此时R2为H，或者R1和R2都可以是甲基或者一起表示为═O; R3，R4和R5各自独立选择自H和较低的烷基基团; R6，R7，R8，R9，R10，R11和R12各自独立选择自H，较低的烷基基团，NH2，卤素（F，Cl和Br），O-烷基，CH2NM2和CF3; R13从H，F，Cl，Br，NO2，NH2，OH，Me，Et，OMe，NMe2和CF3中选择; R14从H，甲基和乙基中选择; W从═CH—和═N—中选择; X从CH2，O，S，SO2，NH和N-较低的烷基中选择; Y1从CO-较低的烷基，CO(CH2)bY3，CO(CH2)bCOY3和CO(CH2)bNHCOY3中选择，其中b为1-3; Y2从OR15，NR16R17和NH(CH2)cCOY3中选择，其中c为1-3; Y3从OR15和NR16R17中选择; R15从H，较低的烷基和(CH2)aR16中选择，其中a为0-4; R16和R17各自独立选择自H，较低的烷基和(CH2)aR16，或者一起为—(CH2)2-Z-(CH2)2—; R18为OH，苯基或从吡啶基，嘧啶基，吡嗪基，呋喃基，噻吩基，吡咯基，咪唑基，吡唑基，噁唑基，异噁唑基，噻唑基，异噻唑基，三唑基，噁二唑基和噻二唑基中选择的芳香杂环，每个芳香杂环可以选择有较低的烷基基团取代物; Z从O，CH2，S，SO2，NH和N-较低的烷基中选择。它们在乳腺癌和前列腺癌，子宫内膜异位症和良性前列腺增生的治疗，调节生育能力以及体外受精方面有用。